N/A
Completed N=32
Financial Incentives to Improve Asthma
Asthma · Medication Adherence
Source: ClinicalTrials.gov NCT05322044 ↗
Enrolled (actual)
32
Serious AEs
12.5%
Results posted
Feb 2025
Primary outcomePrimary: Comparison of Percentage ICS Adherence Between Groups at 12-weeks — 56; 73 percentage adherence
Summary
The aim of this pilot randomised controlled trial is to assess the effectiveness of a short-term financial incentives intervention at bringing about behaviour change, namely short-medium term improvements in inhaled corticosteroid (ICS) adherence and asthma control in children and young people (CYP) with asthma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comparison of Percentage ICS Adherence Between Groups at 12-weeks |
56; 73 | — |
| SECONDARY Proportion of Participants Achieving Good Asthma Adherence (≥80%) |
1; 4; 0; 0 | — |
| SECONDARY Number of Asthma Exacerbation Needing a Course of Oral Corticosteroids (OCS) |
1; 2; 0; 1 | — |
| SECONDARY Asthma Control |
20.50; 20.00; 21.00; 23.00; 22.50; 24.00 | — |
| SECONDARY Exhaled Nitric Oxide |
24; 51; 55.50; 66.50; 46.50; 102 | — |
| SECONDARY Brief Illness Perceptions Questionnaire (B-IPQ) |
26; 33; 23.50; 26; 21.00; 26 | — |
| SECONDARY Habit |
2.75; 2.91; 2.72; 2.50; 2.69; 3.06 | — |
| SECONDARY Self-reported Adherence |
4.20; 4.1; 4.30; 4.20; 4.20; 4.10 | — |
| SECONDARY Change in Percentage ICS Adherence for Control Participants Between 12-weeks and 24-weeks |
56; 31.5 | — |
| SECONDARY Change in Percentage ICS Adherence for Intervention Participants Between 12-weeks and 24-weeks |
73; 39 | — |
| SECONDARY Comparison of Percentage ICS Adherence Between Groups at 24-weeks (Follow-up) |
31.5; 39 | — |
| SECONDARY Total Number of Asthma Attacks Over the Course of the Study |
1; 3 | — |
| SECONDARY Incident Rate Ratio of Asthma Exacerbations |
NA; NA | — |
| SECONDARY Autonomous Motivation |
22.50; 22.50; 22; 20; 26; 21 | — |
| SECONDARY Controlled Motivation |
18.19; 16.81; 14.73; 17.07; 17.67; 15.38 | — |
| SECONDARY Belief in Medicine Questionnaire (BMQ) - Necessity |
15.19; 14.19; 15.53; 16.21; 16.17; 14.38 | — |
| SECONDARY Belief in Medicine Questionnaire (BMQ) - Concern |
15.63; 14.31; 15.33; 15.64; 16.67; 15.31 | — |
| SECONDARY Belief in Medicine Questionnaire (BMQ) - Harm |
12.5; 12; 14; 12; 12.5; 13 | — |
| SECONDARY Belief in Medicine Questionnaire (BMQ) - Over-use |
15; 15; 15; 14; 15.5; 14 | — |
Eligibility Criteria
Inclusion Criteria
- Informed consent obtained from parent/guardian and assent from child.
- CYP with doctor diagnosed asthma presenting to Emergency Department (ED) with a severe asthma exacerbation (as defined by ERS/ATS guidelines).
- Aged between 11 and 17 years old
- Prescribed maintenance inhaled corticosteroids (ICS) (which can include maintenance and reliever therapy MART) for at least 6-months.
- Own their own mobile smartphone (running Android 8 or higher, or iOS 13 or higher)
- Prescribed the following inhalers: Clenil, Flixotide, Symbicort, Seretide
Exclusion Criteria
- Parent/guardian / CYP unable to provide consent / assent
- CYP with other, co-existing respiratory conditions
- Parent/guardian/CYP who are not fluent or able to understand the information provided in English.
- CYP who are involved in other intervention research studies (including CTIMPs)
Data sourced from ClinicalTrials.gov (NCT05322044). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.